Tapering Injured Workers off Prescription Drugs

Similar documents
PRIUM Educational Services Managing Drugs & Chronic Pain in Work Comp

Legacy Pain Management Center New Patient Questionnaire

solutions MEDICATION MIS MANAGEMENT and Chronic Pain 10/4/2016 Opioid Abuse: Current Data Opioid Abuse: Current Data

Subject: Pain Management (Page 1 of 7)

20/0.8mg, 30/1.2mg, Films 90 MME/day Belbuca (buprenorphine) 75mcg, 150mcg, 300mcg, 450mcg 60 units per 90 days

NEW PATIENT QUESTIONNAIRE

Blueprint for Prescriber Continuing Education Program

Practical Pain Management Leah Centanni, MSN, FNP-C, Asst. Clinical Professor CANP Conference March 22, 2014

``Considerations for using opioid drug therapy in workers compensation include patient safety, drug effectiveness and financial impacts

PAIN. TREATMENT TABLES Analgesics. NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose

Prescription Drug Abuse: Colorado and Nationwide

Soma (carisoprodol), Soma Compound (carisoprodol and aspirin), Soma Compound w/ Codeine (carisoprodol and aspirin and codeine)

Opioid Analgesics. Recommended starting dose for opioid-naïve patients

High Risk Medications. University of Illinois at Chicago College of Nursing

PAIN SOLUTIONS NEW PATIENT QUESTIONNAIRE

used for dealing with anxiety. Both of the drugs are also given to patients for dealing with pain activated by damaged or hypersensitive nerves that i

Up and Away with Opioids

Shining a Light on MEDs Understanding morphine equivalent dose

Knock Out Opioid Abuse in New Jersey:

Prior Authorization for Opioid Products Indicated for Pain Management

No Pain, No Gain Pharmacy Patient Pain Counseling Competition

disease or in clients who consume alcohol on a regular basis. bilirubin

Soma (carisoprodol), Soma Compound (carisoprodol and aspirin), Soma Compound w/ Codeine (carisoprodol and aspirin and codeine)

APPENDIX E: HEALTHCARE PRACTITIONER- REPORTED REDUCTION OF PAIN MEDICATION

Session II. Learning Objectives for Session II. Key Principles of Safe Prescribing. Benefits and Limitations of ER/LA Opioids

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain

2009 Workers' Compensation Drug Trend Report. An analysis of trend and a forecast for the future

PATIENT DEMOGRAPHIC INFORMATION

Pharmacology. Definitions. Pharmacology Definitions 8/20/2013. Drug:

Prior Authorization Guideline

Sedative/Hypnotic Agents. Sedative/Hypnotic Agents. Central Nervous System Depressants. Sedative/Hypnotic Agents(cont d) Sleep

Prescription Drugs MODULE 5 ALLIED TRADES ASSISTANCE PROGRAM. Preventative Education: Substance Use Disorder

Managing Narcotics on Workers Comp Claims. Presented By: Craig S. Stern, PharmD, MBA President Pro Pharma Pharmaceutical Consultants, Inc.

Initial Pain Questionnaire

Approaches to Responsible Opioid Prescribing. The Opioid Naïve Patient

Tips for Pain Management

NEW PATIENT INFORMATION SHEET

tramadol sedation in dogs how long does it last for

Baclofen is a GABA-agonist, although its exact mechanism of action remains uncertain. It is known to reduce release of excitatory neurotransmitters.

Opioids: Use, Abuse and Cause of Death. Jennifer Harmon Assistant Director - Forensic Chemistry Orange County Crime Laboratory

9/5/2011. Outline. 1. Past and Current Trends re: RX Abuse 2. Diversion Methods 3. Regulatory Reporting Requirements 4. Q/A

Medications Guide: Public Speaking And Social Anxiety

10 BEFORE THE MEDICAL BOARD OF CALIFORNIA Kimberly Kirchmeyer ("Complainant") brings this Accusation solely in her official

HOW DOES XANAX TREAT VERTIGO

H NDS-ONHealth. Prescription Drug Abuse. Drug overdose death rates in the United States have more than tripled since 1990 and have never been higher.

Prescription Drug Misuse/Abuse in Seniors. April Rovero Founder/Executive Director

Index. Note: Page numbers of article titles are in boldface type.

/2012/TENDER_3/PROTOCOL_2

Pain Management. University of Illinois at Chicago College of Nursing

NEW PATIENTS' INFORMATION SHEET

HYDROCODONE V 2355 PILL STREET VALUE

Pain Management for Adult sickle cell disease patients: Information for patients, relatives and carers

INITIAL COMPREHENSIVE PAIN QUESTIONNAIRE

: Opioid Quantity Limits

A Patient s Guide to Pain Management Medications

PALLIATIVE TREATMENT BY DR. KHRONGKAMOL SIHABAN MEDICAL ONCOLOGIST

CODEINE COUGH SYRUP AND XANAX

Controlled Substance and Wellness Agreement

Opioid Analgesic Treatment Worksheet

RP PERCOCET STREET VALUE

A PATIENT GUIDE FOR MANAGING PAIN

some things you should know about opioids before starting a prescription an informational booklet for opioid pain treatment

Overview. Spasticity. Spasticity. Oral Medications. Spasticity 3/10/2012. Medication Management of Spasticity in the Traumatic Brain Injured Patient

3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years

ANTI-DEPRESSANT MEDICATIONS

Opioids: Use and Misuse/Steven Feinberg, MD; Scott Levy, MD, MPH, FACOEM

Morphine Sulfate Hydromorphone Oxymorphone

Long-Acting Opioid Analgesics

Skeletal Muscle Relaxants Drug Class Prior Authorization Protocol

Long-Acting Opioid Analgesics

Drug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA opioid analgesics) Avinza Butrans

TRAMADOL AND ELEVATED CREATININE

IS ATIVAN LIKE KLONOPIN

Available Strengths. Cost per Rx 325 mg tablet - $ mg tablet - $ mg ER tablet - $ mg capsule - $ mg chewable tablet

Clinical Policy: Opioid Analgesics Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid

SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION

Nociceptive Pain. Pathophysiologic Pain. Types of Pain. At Presentation. At Presentation. Nonpharmacologic Therapy. Modulation

Prescription Drug Dispensing in Oregon

OPIOIDS: THE GOOD, THE BAD, AND EVERYTHING IN-BETWEEN

Technician Training Tutorial: Safety Considerations with Opioids

INITIAL PAIN QUESTIONNAIRE

Ten Tips for Prescribing Controlled Substances. Charlie Reznikoff MD Hennepin County Medical Center

Risk Reduction Strategies in Pain Management

Where is your pain located? Please use the diagram below to indicate where most of your pain is located.

PSYCHOTROPIC MEDICATION AND THE WORKPLACE. Dr. Marty Ewer 295 Fullarton Road Parkside

COMPREHENSIVE REHABILITATION PAIN QUESTIONNAIRE. Date of Visit. Statement of Problem: Date of Injury/onset of condition: Date of birth: Age

Pain Management. Craig Hospital 2015 All Rights Reserved Rev. 1/2015 Publication # 777 Page 1 of 11

Hydrocodone 10mg vs oxycodone 10 mg. What is the difference between oxycontin and oxycodone hcl 1 acetaminophen with oxycodone and roxicodone 5mg

9/30/2017. Case Study: Complete Pain Assessment and Multimodal Approach to Pain Management. Program Objectives. Impact of Poorly Managed Pain

ten questions you might have about tapering (and room for your own) an informational booklet for opioid pain treatment

A Patient s Guide to The Medication Approach to Chronic Pain

Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT

PAIN RELIEF AFTER SURGERY

Tapering Opioids Best Practices*

Managing Pain after Transplant Denice Economou, RN,MN,CHPN,AOCN

Doctor Discussion Guide

Guidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

3/3/2015 CHRONIC PAIN MARGARET ZOELLERS, MSN, APRN

EXTENDED RELEASE OPIOID DRUGS

Slide 1. Slide 2. Slide 3. Opioid (Narcotic) Analgesics and Antagonists. Lesson 6.1. Lesson 6.1. Opioid (Narcotic) Analgesics and Antagonists

Transcription:

www.prium.com Tapering Injured Workers off Prescription Drugs

Learning Objectives 1. Define polypharmacy complexities 2. Explain the biopsychosocial model 3. Outline the weaning process 4. Examine real life examples Good and Bad

Polypharmacy Complexities

Polypharmacy The Enemy of Function PAIN Opioid fentanyl? Insomnia Lethargy Atrophy zolpidem modafinil carisoprodol Depression Sexual dysfunction Constipation Addiction duloxetine sildenafil stool softener buprenorphine All of this makes the pain harder to identify and treat

Polypharmacy Opioid (narcotic) Pain Purpose: Relieve pain by acting directly on the central nervous system (oral, topical). Refills are generally prohibited without new script Possible Side Effects: Sedation, drowsiness, impairments, constipation, respiratory depression, nausea, headache, stomach pain. Extremely high potential for abuse, dependence, addiction and diversion On-label Uses: Before/during/immediately after surgery, cancer and AIDS patients Red Flags: Used more than 6 contiguous months, DOI of more than 3 years, no change in levels of pain or function, aggregate dosage exceeds 120mg MED/day ACOEM s new guidelines establish 50mg MED/day Examples: Actiq (Fentanyl lollipop), Exalgo (Hydromorphone ER), Avinza / Kadian (Morphine ER), OxyContin (Oxycodone ER), Nucynta (Tapentadol), Duragesic (Fentanyl transdermal), Ultram (Tramadol)

Polypharmacy Morphine Equivalent Dosage (MED) A method developed to adjust for the various potency of opioids into a common measurement (morphine, which would be a 1:1 ratio) Per ODG, the Factor to be used when calculating MED Codeine - 0.15 Fentanyl (Actiq) oral transmucosal - 10-100 Hydrocodone - 1 Hydromorphone (Exalgo) - 4 Methadone, 41 to 60mg per day - 10, > 60mg per day - 12 Oxycodone (OxyContin) - 1.5 Oxymorphone (Opana) - 3 (Quantity / Day Supply) = Daily Pill Count * Dosage * MED Factor = MED

Polypharmacy NSAID (non-steroidal anti-inflammatory drug) Pain Purpose: Relieve pain and inflammation by reducing enzymes and hormones that cause inflammation and pain in the body (oral, topical) Possible Side Effects: Nausea, vomiting, diarrhea, constipation, decreased appetite, rash, dizziness, headache, and drowsiness, fluid retention. The most serious side effects are kidney failure, liver failure, ulcers and prolonged bleeding after an injury or surgery On-label Uses: Acute musculoskeletal pain conditions, rheumatoid and osteoarthritis Red Flags: Used more than 6 contiguous months, aggregate dosage exceeds 3200mg/day, DOI of more than 3 years, prescriptions when OTC would suffice Examples: Flector patches, Voltaren (Diclofenac Sodium), Celebrex (Celecoxib), Ketoprofen, Mobic (Meloxicam), Relafen (Nabumetone)

Polypharmacy Skeletal Muscle Relaxant Pain Purpose: Relax muscles that control the skeleton Possible Side Effects: Sedation, drowsiness, dizziness. Others include central nervous system depression (Baclofen), hepatotoxicity (Dantrolene), dependence and withdrawal symptoms (Carisoprodol), toxicity in overdose and in combination with other substances (Cyclobenzaprine), low blood pressure (Tizanidine) On-label Uses: For spasticity (multiple sclerosis, spinal cord injury, traumatic brain injury, cerebral palsy, and post-stroke syndrome). For muscle spasms (fibromyalgia, tension headaches, myofascial pain syndrome, and mechanical low back pain or neck pain) Red Flags: Used more than 2 contiguous months, DOI of more than 3 years, no rehab program with active treatment Examples: Soma (Carisoprodol), Amrix (Cyclobenzaprine), Valium (Diazepam), Lioresal (Baclofen), Skelaxin (Metaxalone), Zanaflex (Tizanidine)

Polypharmacy Skeletal Muscle Relaxant Soma (Carisoprodol) Muscle relaxer that works by blocking pain sensations between the nerves and the brain. The drug is intended to cause sedation, muscle relaxation and relief from structural pain. Interactions: 662 drug interactions, 3 disease interactions, alcohol Central respiratory depression may occur, particularly at high doses Stop using carisoprodol and call your doctor at once if you have any of these serious side effects: paralysis (loss of feeling); extreme weakness or lack of coordination; feeling light-headed, fainting; fast heartbeat; seizure (convulsions); vision loss ; or agitation, confusion.

Polypharmacy Anti-Depressant Pain Purpose: Relieve symptoms of depressive disorders that can negatively affect the healing process Possible Side Effects: Upset stomach, dry mouth/eyes, increase in skin sensitivity, insomnia, drowsiness, changes in sex drive, changes in appetite and confusion. Serious side effects that require medical attention include constipation, difficulty in speaking, irregular heartbeat, trembling, stiffness of limbs, hallucinations and thoughts of suicide On-label Uses: Diagnosis of depression or anxiety Red Flags: Lack of objective findings supporting continued use, psych not accepted as compensable or pre-existing Examples: Wellbutrin (Bupropion), Lexapro (Escitalopram), Zoloft (Sertraline), Elavil (Amitriptyline), Effexor (Venlafaxine)

Polypharmacy Benzodiazepine Pain Purpose: Do not have any pain-relieving properties themselves, and are generally recommended to avoid in individuals with pain Possible Side Effects: Sedation, dizziness, weakness, unsteadiness, feeling of depression, loss of orientation, headache, sleep disturbance, physical dependence, withdrawal symptoms upon disuse On-label Uses: Anxiety and seizure disorders, insomnia, anesthesia, muscle relaxation, alcohol withdrawal Red Flags: Use for more than 2-4 weeks, excessive sedation, combination with opioids and/or Soma, alcohol consumption Examples: Xanax (Alprazolam), Valium (Diazepam), Ativan (Lorazepam), Klonopin (Clonazepam), Restoril (Temazepam)

Polypharmacy Treatment Red Flags Opioid dosage exceeding 50-120mg MED per day Acetaminophen dosage exceeding 4000mg per day NSAID dosage exceeding 3200mg per day Opioids used for more than 2 contiguous months after surgery Muscle relaxants used for more than 2 contiguous months NSAIDs used for more than 6 contiguous months Benzodiazepines used for more than 4 contiguous weeks No exit strategy by the prescriber Prescriber not utilizing the state s PDMP

Polypharmacy Treatment Red Flags Topical analgesics Anti-narcoleptic drugs (Provigil, Nuvigil) Hormonal supplements Spinal Cord Stimulator / Intrathecal Pump and topical / oral analgesics Drug regimen that has automatic refills More than one prescribing physician involved in the overall drug regimen No opioid treatment agreement No urine drug monitoring or inconsistent results No liver / kidney toxicity tests where applicable Rx refills without doctor visits The Future Medical desk $10,000 Rx costs per year

The BioPsychoSocial Model

Treating Pain Multi-Modal Therapy Pharmacotherapy 1 Interventional Approaches 2 Psychological Support 3 Complementary and Alternative Medicine 4 Lifestyle Change 5 Physical Medicine and Rehabilitation 6 1. Krenzischek DA et al. J Perianesth Nurs. 2008;23(Suppl 1):S28-S42. 2. Lordon SP. Curr Pain Headache Rep. 2002;6(3):202-206. 3. Townsend CO et al. J Clin Psychol. 2006;62(11):1433-1443. 4. Patel G et al. Med Clin N Am. 2007;91(1):141-167. 5. Freedman MK et al. Arch Phys Med Rehabil. 2008;89(3 suppl 1):S56-S60. 6. Stanos SP et al. Anesthesiol Clin. 2007;25(4):721-759.

Bio-psycho-social What happens between the ears and at home is as important as what is physically wrong with the body

BioPsychoSocial Complications 1. Psychological makeup Catastrophic thinking Fear / pain / movement avoidance Perceived injustice Personality disorders Predisposition to addictive behaviors 2. Social environment Ethnic or cultural differences Family life Socio-economic circumstances 3. Co-morbidities Diabetes, hypertension, obesity, smoking, osteoarthritis All of this increases as the patient ages

BioPsychoSocial Due Diligence Risk management before prescribing Prior substance abuse Personal or family substance abuse history Tool: DAST (Drug Abuse Screening Test) Potential addiction/dependence issues Adverse childhood experiences (ACE), www.cdc.gov/ace Neglect Physical, emotional, sexual abuse Tools Before: Diagnosis, Intractability, Risk, Efficacy (DIRE) Opioid Risk Tool (ORT), Screener and Opioid Assessment for Patients with Pain (SOAPP) Tools During: Current Opioid Misuse Monitor (COMM)

BioPsychoSocial Due Diligence Psychological makeup Mental illness Psychological stress Coping skills Tool: Patient Health Questionnaire (PHQ-9)

The Weaning Process

The Weaning Process Patient More Art than Science 1. Motivation of the patient The patient must make a life change Evaluate Psychological and/or physical dependence Anxiety and/or depression Family and other interpersonal factors Explain risks and potential benefits

The Weaning Process Patient Identify how patient will manage pain with less/no dosage Recovery lifestyle Coping skills Function Per the AMA Guides March/April 2011 Newsletter, 21 of 23 patients in the study reported a significant decrease in pain after detoxification Functional Restoration is a natural consequence of Weaning!

The Weaning Process Physician More Art than Science 2. Competence of the provider Is the current drug regimen appropriate? Can the treating physician facilitate the weaning? In-patient / out-patient? Is CBT / MI required first? Is the goal reduction in dosage or removal of drugs?

The Weaning Process Physician Manage the withdrawal symptoms Assess co-morbidities and complicating factors Separate pain management from disease management Create a tapering strategy An Analysis of Drug Therapy Tapering Guidelines, whitepaper co-authored by Mark Pew and Dr. Kimberly Vernachio Started with 257 guidelines, only 18 met selection criteria ZERO addressed how to taper polypharmacy regimens Physicians have little guidance for how to taper complicated drug regimens

The Weaning Process Standard of Care Per Official Disability Guidelines (ODG) For patients that are not addicted and on relatively low dosage Taper by 20-50% per week Otherwise a slower process is suggested 10% every 2-4 weeks, down to 5% once ⅓ the original dosage Each patient is different in response and duration

The Good, Bad and Indecipherable Real Examples from the front lines